The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Overview of attention for article published in Experimental Hematology & Oncology, November 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 tweeters

facebook: 1 Facebook page

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 26 Mendeley

Summary Twitter Facebook Dimensions citations

So far, Dimensions has found 26 publications that cite this research output.

26

The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.

A CTLA-4 blocking strategy based on Nanobody in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects

Article in BMC Cancer (September 2021)

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Article in Frontiers in Immunology (August 2021)

A CTLA-4 Blocking Strategy Based on Nanobaby in Dendritic Cell-stimulated Cytokine-induced Killer Cells Enhances Their Anti-tumor Effects

Preprint in Research Square (February 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.